Related Experiment Videos
Epothilone B induces glioblastoma cell death via survivin down-regulation
1Department of Biological Sciences, Grambling State University, Grambling, LA 71245, USA. quickq@gram.edu
Aim:
The clinical resistance of glioblastomas to chemotherapeutic agents can be attributed to drug efflux pumps, such as P-glycoprotein, which contributes to reduce drug efficacy. The present study examined the utility of epothilone B, which is not a substrate for P-glycoprotein, on glioblastoma cells.
Methods:
In vitro methods with glioblastoma cells varying in p53 status were used to assess the efficacy of epothilone B to induce anti-neoplastic responses. Immunofluorescence and ELISA procedures were used to examine levels of tubulin and survivin in epothilone B treated glioblastoma cells, while acridine orange labeling was used to detect the mode of epothilone B induced cell death.
Results:
A clinically achievable concentration of epothilone B induced a cytotoxic response in p53 mutant glioblastoma cells, as a consequence of survivin down-regulation and tubulin redistribution, while a cytostatic response was observed in p53 null glioblastoma cells with a modest increase in survivin expression post-epothilone B treatment. However, p53 wild-type glioblastoma cells did not sustain a positive anti-tumorigenic response to epothilone B.
Conclusion:
Epothilone B, induced positive differential responses in glioblastoma cells with abnormal p53 status, but not in p53 wild-type cells. This suggests that epothilone B is a potential alternative to classic microtubule inhibiting agents (ie vincristine, paclitaxel) used to treat clinical glioblastomas with p53 mutations.
Insights
Epothilone B shows promise against glioblastoma by overcoming drug resistance in cells with abnormal p53 status. This microtubule-targeting agent offers a potential new treatment option for specific glioblastoma patient populations.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastomas often develop clinical resistance to chemotherapy due to drug efflux pumps like P-glycoprotein, reducing treatment efficacy.
- Epothilone B is a novel chemotherapeutic agent that is not a substrate for P-glycoprotein, suggesting potential efficacy against resistant glioblastomas.
Purpose of the Study:
- To investigate the anti-neoplastic effects of epothilone B on glioblastoma cells with varying p53 statuses.
- To determine the molecular mechanisms underlying epothilone B's efficacy, including its impact on tubulin and survivin levels and cell death pathways.
Main Methods:
- In vitro studies utilized glioblastoma cell lines with different p53 statuses (mutant, null, wild-type).
- Immunofluorescence and ELISA were employed to quantify tubulin and survivin expression.
- Acridine orange labeling assessed the mode of cell death induced by epothilone B.
Main Results:
- Epothilone B induced cytotoxicity in p53 mutant glioblastoma cells, linked to survivin down-regulation and tubulin redistribution.
- A cytostatic effect was observed in p53 null glioblastoma cells, with a minor increase in survivin.
- p53 wild-type glioblastoma cells did not exhibit a significant anti-tumorigenic response to epothilone B.
Conclusions:
- Epothilone B demonstrates differential efficacy in glioblastoma cells, particularly those with aberrant p53 status.
- The findings suggest epothilone B could be a viable alternative to traditional microtubule inhibitors for glioblastomas with p53 mutations.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle